vigencell gout treatment
Scope
Date
~
-
Bio & Pharma
ViGenCell obtains approval for HLA-B5801 genetic diagnostic kit for adverse reactions to gout treatment
ViGenCell, a company specializing in immunotherapy, announced on Friday that it has obtained approval from the Ministry of Food and Drug Safety (MFD...
Oct 25, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion's anti cancer drugs hold 90% market share in C.America
South Korea’s Celltrion Inc. said on Friday that its cancer treatments have captured a 90% market share in several Central American countries....
Oct 11, 2024 (Gmt+09:00)
-
Bio & Pharma
Osstem Implant to boost digital dentistry business
South Korea's Osstem Implant Co., the world’s fourth-largest dental implant maker, will enhance its software system of digital dentistry. ...
Sep 24, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to supply breast, stomach cancer treatment to Brazil
Celltrion Inc., South Korea’s largest biosimilar maker, announced on Friday that its breast and stomach cancer treatment "Herzuma" (active ing...
Sep 13, 2024 (Gmt+09:00)
-
Bio & Pharma
SK Group’s 3rd-generation daughter comes to the fore
Chey Yoon-chung, the eldest daughter of SK Group Chairman Chey Tae-won, unexpectedly made her debut during an SK Biopharmaceuticals Co. video confer...
Aug 30, 2024 (Gmt+09:00)
-
Mergers & Acquisitions
GS E&C in talks to sell entire stake in GS Elevator to Chinese firm
South Korea’s GS Engineering & Construction Corp. (GS E&C) is in talks to sell its entire stake in GS Elevator Co. to a Chinese strate...
Aug 14, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion gets approval of Steqeyma in Canada
South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Steqeyma, a biosimilar of the autoimmune dise...
Jul 31, 2024 (Gmt+09:00)
-
Bio & Pharma
GC Biopharma sells HK subsidiary to CR Pharm Group for $254 mn
South Korea’s GC Biopharma Corp. announced on Wednesday that it signed a share purchase agreement (SPA) to sell all its shares in its Hong Kon...
Jul 18, 2024 (Gmt+09:00)
-
Bio & Pharma
LG Chem launches Synovian in China
South Korea's LG Chem Ltd. announced on Wednesday that it launched its homegrown new drug for osteoarthritis Synovian (marketed in China as Hyruan O...
Jul 03, 2024 (Gmt+09:00)
-
Bio & Pharma
Handok gets Biocon's obesity drug exclusive distribution in S.Korea
South Korean pharmaceutical company Handok Inc. announced on Friday that it signed an exclusive domestic sales and distribution agreement with India...
May 24, 2024 (Gmt+09:00)
-
Bio & Pharma
Investors dump Korean biotech HLB stocks on FDA rejection
HLB Co. and its affiliate stocks tumbled on Friday on news that the South Korean biotech group’s highly anticipated new cancer treatment Rivoc...
May 17, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to supply Remsima, Herzuma to Peru
South Korea's Celltrion Inc. announced on Thursday that it secured a contract to supply its biosimilars for autoimmune disease treatment and antican...
May 02, 2024 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis gets OK to sell Stelara biosimilar in Europe
South Korea's Samsung Bioepis has received approval from the European Commission to sell Pyzchiva, a biosimilar of the autoimmune disease Stelara.&n...
Apr 23, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion releases Remsima SC in Denmark
South Korea's Celltrion Inc. announced on Thursday that it released its autoimmune disease treatment Remsima SC (infliximab) in Denmark. Remsima SC ...
Apr 19, 2024 (Gmt+09:00)
-
Future mobility
Hyundai, Toray to team up to develop mobility materials
Hyundai Motor Group said on Thursday it has signed a strategic partnership agreement with Japan's Toray Industries Inc. to jointly develop carbon fi...
Apr 18, 2024 (Gmt+09:00)
-
Bio & Pharma
Genesystem enters Indian tuberculosis treatment market
Genesystem, a South Korean biotech company said on Tuesday that it will export 20 on-site tuberculosis (TB) diagnostic devices and 6,000 TB test kit...
Mar 27, 2024 (Gmt+09:00)
-
Bio & Pharma
Reversing age possible in a decade: Harvard Prof. David Sinclair
Humans will be able to control biological age and reverse their age in 10 years with advancements in medical science and live up to around 120, abou...
Mar 18, 2024 (Gmt+09:00)
-
Bio & Pharma
Vivid Health gets seed round from Kakao Ventures
Vivid Health, a South Korean startup that operates an obesity treatment management platform announced on Wednesday that it got a seed round investme...
Mar 06, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion ships initial supply of Zymfentra to US
South Korea's Celltrion Inc. announced on Wednesday that it shipped the first supply of its subcutaneous injection type of the autoimmune disease tr...
Feb 29, 2024 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis to supply Hadlima to US government
South Korea’s Samsung Bioepis and the US-based Organon, the local partner company of Samsung group's biopharmaceutical research and developmen...
Feb 21, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to deliver three treatments to Peru
South Korea’s Celltrion Inc. announced on Thursday that it will supply three treatments, including its blood cancer drug Truxima (rituximab) t...
Feb 15, 2024 (Gmt+09:00)
-
Korean Investors
Samsung Asset to launch S.Korea's first obesity treatment ETF
Korea Exchange announced on Thursday that it will list Samsung Asset Management's "KODEX Global Obesity Treatment Top 2 Plus exchange-traded fund (E...
Feb 08, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to supply Remsima SC, Yuflyma to Norway
South Korea's Celltrion Inc. announced on Wednesday that it will supply its autoimmune disease treatments Remsima SC (infliximab) and Yuflyma, the...
Feb 07, 2024 (Gmt+09:00)
-
Bio & Pharma
Aprogen gets OK Phase 3 trials in India for Herceptin biosimilar
South Korea’s biopharmaceutical company Aprogen Inc. announced on Monday that its Phase 3 clinical trial for a biosimilar of Herceptin (trastu...
Feb 05, 2024 (Gmt+09:00)
-
Bio & Pharma
Kobiolabs gets Chinese patent for obesity treatment strain
South Korean microbiome-based new drug development company Kobiolabs Co. announced on Wednesday that it has a patent for its obesity treatment strai...
Jan 17, 2024 (Gmt+09:00)
-
Bio & Pharma
JW Pharma takes gout drug Epaminurad to Malaysia for phase 3
South Korea's JW Pharmaceutical Corp., announced on Monday that it has received approval from the Malaysian National Pharmaceutical Regulatory Age...
Jan 15, 2024 (Gmt+09:00)
-
Bio & Pharma
Kobiolabs gets US patent for oral obesity drug candidate
Kobiolabs Co., a South Korean microbiome-based new drug development company, announced on Wednesday that it has a patent for Roseburia intestinalis ...
Jan 10, 2024 (Gmt+09:00)
-
Bio & Pharma
Inventage Lab, Yuhan to co-work for obesity treatment
South Korea’s Inventage Lab Inc. announced on Friday that it has signed a joint development agreement with Yuhan Corp. for a long-acting inj...
Jan 05, 2024 (Gmt+09:00)
-
Bio & Pharma
ViGenCell, NK/T cell lymphoma treatment ‘VT-EBV-N’ designated as orphan drug in Europe
ViGenCell, a company specializing in immune cell therapy, announced on the 19th that its NK/T cell lymphoma treatment "VT-EBV-N" has been designated...
Dec 27, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for approval of Xolair biosimilar in Canada
South Korean biopharmaceutical company Celltrion Inc. announced on Wednesday that it has applied for CT-P39, a biosimilar of the treatment of asth...
Dec 27, 2023 (Gmt+09:00)
Latest News
- 1 TheBorn Korea eyes M&As, overseas expansion after planned $73.7 million IPO
- 2 Korea's Hana Bank to promote foreigners as managers in overseas units
- 3 Samsung to unveil 400-layer bonding vertical NAND for AI servers by 2026
- 4 Korean LPs sharpen focus on GPs' post-investment management
- 5 LG Energy Q3 profit more than doubles on higher sales